Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia

Bruno C. Medeiros, Steven M. Chan, Naval G. Daver, Brian Jonas, Daniel A. Pollyea

Research output: Contribution to journalReview article

Abstract

Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML). Monitoring patients for measurable residual disease (MRD) is helpful to identify those at risk for relapse. Hypomethylating agents are being investigated as post-remission therapy. Identification of recurrent genetic alterations that drive disease progression has enabled the design of new, personalized approaches to therapy for patients with AML. Emerging data suggest that targeted post-remission therapy, alone or in combination with chemotherapy, may improve outcomes. Results of ongoing clinical trials will further define potential clinical benefits.

Original languageEnglish (US)
JournalAmerican Journal of Hematology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Acute Myeloid Leukemia
Survival
Recurrence
Physiologic Monitoring
Therapeutics
Combination Drug Therapy
Disease Progression
Clinical Trials

ASJC Scopus subject areas

  • Hematology

Cite this

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. / Medeiros, Bruno C.; Chan, Steven M.; Daver, Naval G.; Jonas, Brian; Pollyea, Daniel A.

In: American Journal of Hematology, 01.01.2019.

Research output: Contribution to journalReview article

Medeiros, Bruno C. ; Chan, Steven M. ; Daver, Naval G. ; Jonas, Brian ; Pollyea, Daniel A. / Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. In: American Journal of Hematology. 2019.
@article{0882353629bf4edf8e08fa0c80ead2ef,
title = "Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia",
abstract = "Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML). Monitoring patients for measurable residual disease (MRD) is helpful to identify those at risk for relapse. Hypomethylating agents are being investigated as post-remission therapy. Identification of recurrent genetic alterations that drive disease progression has enabled the design of new, personalized approaches to therapy for patients with AML. Emerging data suggest that targeted post-remission therapy, alone or in combination with chemotherapy, may improve outcomes. Results of ongoing clinical trials will further define potential clinical benefits.",
author = "Medeiros, {Bruno C.} and Chan, {Steven M.} and Daver, {Naval G.} and Brian Jonas and Pollyea, {Daniel A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/ajh.25484",
language = "English (US)",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia

AU - Medeiros, Bruno C.

AU - Chan, Steven M.

AU - Daver, Naval G.

AU - Jonas, Brian

AU - Pollyea, Daniel A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML). Monitoring patients for measurable residual disease (MRD) is helpful to identify those at risk for relapse. Hypomethylating agents are being investigated as post-remission therapy. Identification of recurrent genetic alterations that drive disease progression has enabled the design of new, personalized approaches to therapy for patients with AML. Emerging data suggest that targeted post-remission therapy, alone or in combination with chemotherapy, may improve outcomes. Results of ongoing clinical trials will further define potential clinical benefits.

AB - Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML). Monitoring patients for measurable residual disease (MRD) is helpful to identify those at risk for relapse. Hypomethylating agents are being investigated as post-remission therapy. Identification of recurrent genetic alterations that drive disease progression has enabled the design of new, personalized approaches to therapy for patients with AML. Emerging data suggest that targeted post-remission therapy, alone or in combination with chemotherapy, may improve outcomes. Results of ongoing clinical trials will further define potential clinical benefits.

UR - http://www.scopus.com/inward/record.url?scp=85065233436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065233436&partnerID=8YFLogxK

U2 - 10.1002/ajh.25484

DO - 10.1002/ajh.25484

M3 - Review article

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

ER -